What Is the Serum Ferritin Level Required to Diagnose Iron Deficienc…

Robert Means

ASH 2024 Summary: Highlights in AML, MDS, and ALL

2024 ASH Annual Meeting Insights Hub

T. Badar

ASH 2024 Summary: Highlights in Adult ALL and Implications for Pract…

2024 ASH Annual Meeting Insights Hub

R. Cassaday

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

ASH 2024 Summary: Highlights in Ph- ALL

2024 ASH Annual Meeting Insights Hub

F. Haddad

Delayed Diagnosis and Diagnostic Imprinting in Pediatric CNS Tumors:…

Ibrahim Qaddoumi

Steroid-Refractory GVHD Updates

Roswell Park Comprehensive Cancer Center

S. Holtan

ASH 2024 Summary: Highlights in Ph+ ALL

2024 ASH Annual Meeting Insights Hub

F. Haddad

Recent Updates on Blinatumomab in ALL: FDA Approval in 1L and Incorp…

Sarah Tasian

Tandem 2025 Insights: PTCy-Based GVHD Prophylaxis After Mismatched U…

Insights from 2025 Tandem Annual Meeting

M. Al Malki

Overview and Updates in Brain Tumors

Henry Friedman

AML and MDS Highlights & Key Takeaways

Insights from 2023 ASH Annual Meeting

T. Badar

Acute GVHD: Demographics, Diagnosis, Pathophysiology, and Advancemen…

City of Hope

A. Salhotra

Updates in ALL: Incorporating Immunotherapy in Frontline Management

Talha Badar

ALL in Adults: Overview and Recent Advances

Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course

R. Cassaday

Treating Adult B-ALL: CAR-T vs. Bispecifics vs. Monoclonals

Marlise R. Luskin

BRAF/MEK Targeted Therapy in Adult and Pediatric Glioma: Insights an…

Johns Hopkins

K. Schreck

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

Incorporation of Targeted and Immunotherapies in ALL

XV Eurasian Hematology-Oncology Congress - EHOC 2024

H. Kantarjian

Axatilimab in cGVHD: Mechanism of Action and Comparison With Current…

Noah Merin